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ABSTRACT

Breast cancer affects 1 in 8 women in the United States and is the second most
commonly diagnosed cancer among women. Many treatment options, such as
chemotherapy or surgery, are invasive, ineffective, or detrimental to the body.
It has been previously demonstrated that tannic acid has anti-cancer properties
and is effective in killing cancer cells while not adversely affecting healthy cells. Tannic
acid crosslinks collagen type I. We have proposed using tannic acid crosslinked collagen
type I beads to fill in the void left after surgery while simultaneously treating any
remaining cancer cells after a breast cancer patient has a lumpectomy. This will aid in
killing any remaining cancer cells while helping to regrow the void left in the tissue by
first growing the patient’s adipocytes on the beads before delivery.
Matrigel®, an extracellular membrane-based (ECM) hydrogel is
thermoresponsive, which is ideal for the matrix that will be used. Expanding on previous
work, adipocyte-seeded beads are mixed with Matrigel® and placed in Transwell inserts
should allow us to determine if TA is capable of diffusing out the matrix and treating the
HER2+ breast cancer cells in the bottom of the wells. Imaging and cell counting
determined that tannic acid had an effect on the HER+ breast cancer cell. Western blots
were conducted to determine changes proteins in protein expression after three days of
treatment with varying concentrations of tannic acid. FC assays determined the amount of
tannic acid in the media after the treatment period. The permeability of tannic acid and
ability to diffuse through the gel is important for efficient treatment of breast cancer cells.
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The findings from this proof of concept experiment will allow for further research
to be performed on novel cancer treatments that are less invasive for patients. Future
research includes finding an alternative matrix in which to deliver these cells that has
properties like Matrigel®. Additionally, ideal bead size and specific concentration of
tannic acid will be identified to ensure beads are deliverable and effective.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND
1.1 Project Overview
A current treatment for breast cancer is surgery to remove the tumor from the
breast, which results in a void. This project aims to create collagen type I beads
crosslinked with tannic acid (TA) to prevent the recurrence of breast cancer and to help
fill the void left after surgery. Figure 1.1 shows the hypothetical method in which beads
are created and seeded with a patient’s adipocytes, loaded into a syringe, and injected into
the surgery site. The collagen is remodeled as the adipocytes grow and attach to the
beads. This allows for the release of the TA, which then interacts with any remaining
cancer cells. The TA then induces apoptosis in the cancer cells.

Figure 1.1: Tannic acid collagen type I-crosslinked beads with patient’s adipocytes
seeded form the basis for a tissue regeneration matrix with anti-cancer properties.

1.2 Breast Cancer Overview
Breast cancer is a type of cancer that develops from the cells within the breast
(American Cancer Society, 2017). Although it can present itself differently in patients,
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typical signs and symptoms of breast cancer are skin changes (such as redness or
swelling), an increase in size or change in shape of the breasts, general pain in/on any
part of the breast, irritated or itchy breasts, changes in breast color, and many others
(Cancer Treatment Center of America, 2017). Briefly, breast cancer begins with a
mutation in cells within the breast that allows these mutated cells to grow out of control,
which results in a tumor. Most forms of breast cancer begin in the ducts that carry milk to
the nipple, while others start in the alveolar cells that make milk (Cancer Treatment
Center of America, 2017). Breast cancer spreads once the cancer cells reach the blood or
lymph system and are carried to other parts of the body (American Cancer Society,
2017). Tumors can be benign, meaning they are not a threat, or malignant, meaning they
are cancer and can spread to different parts of the body (Cancer Treatment Center of
America, 2017). Though breast cancer is predominantly found in women, it can also
affect men (National Breast Cancer Foundation, 2017).
Breast cancer is diagnosed several different ways, including imaging tests such as
mammograms or ultrasound, or a biopsy, which is completed after an abnormal
mammogram (American Cancer Society, 2017). Some biopsies use a needle, while others
use an incision. A tissue sample is taken to a lab where a pathologist analyzes it and
determines if the tissue is cancer. A biopsy is the only sure way to diagnose a patient with
breast cancer (American Cancer Society, 2017).

1.3 Breast Cancer Statistics
Breast cancer is the most commonly diagnosed cancer among women in the USA
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and has the second highest death rate for cancers among women (American Cancer
Society, 2017). Data from 2009-2013 indicate that there were 123.3 new cases and 21.1
deaths per 100,000 women, making this a relevant problem in modern society (American
Cancer Society, 2017). Recent improvements in mammography screening, improved
treatments, and early detection have helped to decrease the mortality rate in the past
several years. However, there is still a need to develop better treatment methods as it is
predicted that there will be 252,710 new cases of invasive breast cancer in 2017
(American Cancer Society, 2017).

1.4 Classifications of Breast Cancer
1.4.1 Breast Cancer Stages
The stages of breast cancer are determined based on the size of the tumor within
the breast, the number of lymph nodes affected, and signs indicating whether the breast
cancer has invaded other organs (American Cancer Society, 2017).

1.4.1.1 Stage 0
Stage 0 breast cancer is characterized as a non-invasive cancer where abnormal
cells have been found in the breast. In this stage, there is no evidence of cancer cells or
non-cancerous abnormal cells invading other parts of the breast (American Cancer
Society, 2017).
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1.4.1.2 Stage I
Stage 1 breast cancer is an invasive breast cancer in which cancer cells are
invading the normal surrounding breast tissue. It can be divided into two subcategories:
Stage IA and Stage IB (American Cancer Society, 2017).
Stage IA is characterized by:


tumors that are up to 2 cm



the cancer has not spread outside the breast or into any lymph nodes

Stage IB indicates:


there is not tumor in the breast, but rather small groups of cancer cells in the
lymph nodes



or there is a tumor in the breast no more than 2 cm



or there are small groups of cancer cells in the lymph nodes

1.4.1.3 Stage II
Stage 2 breast cancer is divided into two subcategories: IA and IB (American
Cancer Society, 2017).
Stage IIA implies:


no tumor can be found in the breast, but cancer is found in 1-3 axillary lymph
nodes



or the tumor measures greater than 2 cm and has spread to the axillary lymph
nodes



or the tumor is between 2-5 cm but has not spread to the axillary lymph nodes
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Stage IIB is characterized by


a tumor between 2-5 cm and small groups of breast cancer cells in the lymph
nodes



or a tumor between 2-5 cm along with cancer in 1-3 axillary lymph nodes or to
lymph nodes near the breastbone



or a tumor larger than 5 cm that has not spread to the axillary lymph nodes

1.4.1.4 Stage III
Stage III breast cancer can be divided into three subcategories: IIIA, IIIB, and
IIIC (American Cancer Society, 2017).
Stage IIIA indicates:


no tumor is found in the breast or the tumor may be any size



cancer is found in 4-9 axillary lymph nodes or lymph nodes near the breastbone



or the tumor is larger than 5 cm and there are small groups of breast cancer cells
found in the lymph nodes



or the tumor is larger than 5 cm and the cancer has spread to 1-3 axillary lymph
nodes or to the lymph nodes near the breastbone

Stage IIIB denotes:


the tumor may be any size and has spread to the chest wall and/or skin of the
breast and has caused swelling or an ulcer



or the cancer may have spread to up to 9 axillary lymph nodes



or the cancer may have spread to lymph nodes near the breast bone
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Stage IIIC is an invasive cancer in which:


there may be no sign of cancer in the breast



or if there is a tumor, it may be any size and have spread to the chest well and/or
the skin of the breast



cancer may have also spread to 10 or more axillary lymph nodes



or the cancer has spread to lymph nodes above the collarbone



or the cancer has spread to axillary lymph nodes or to lymph nodes near the
breastbone

1.4.1.5 Stage IV
Stage IV breast cancer indicates that the cancer is invasive and has spread beyond
the breast and nearby lymph nodes to other organs of the body. This stage can be
described as “advanced” or “metastatic” (American Cancer Society, 2017).

1.5 Hormone receptor & HER2 classifications
Breast cancer can be classified by the presence or absence of hormone receptors
(such as estrogen receptor and progesterone receptor) and the status of the HER2 protein
(human epidermal growth factor receptor-2) (American Cancer Society, 2017). After a
pathological examination, the cancer is classified as hormone receptor-positive or receptornegative. For example, a cancer could be assigned the classification of estrogen receptorpositive (ER+) and progesterone receptor-positive (PR+), HER2-positive, triple positive
(presence of all three receptors), or triple negative (absence of all three receptors). Breast
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cancers that are classified as ER+ have the best prognosis, while those that are classified as
triple negative have the worst prognosis (American Cancer Society, 2017).

1.6 Clinical Treatment Options
Current breast cancer treatment options include surgical intervention, radiation
therapy, chemotherapy, hormone therapy, and targeted therapy (American Cancer Society,
2017). Many factors influence the choice of treatment option, such as patient’s age, general
health, patient preferences, the stage of the tumor, the tumor’s subtype, and genomic
markers. Surgery as a treatment for breast cancer involves the removal of the tumor and
some surrounding healthy tissue (American Cancer Society, 2017c). Radiation therapy
uses high-energy x-rays or other particles to kill cancer cells. Chemotherapy is the use of
drugs to destroy cancer cells by stopping the cancer’s ability to grow and divide.
Chemotherapies are administered intravenously or orally. Hormonal therapy is commonly
used for tumors that test positive for either estrogen or progesterone receptors and involves
the blocking of the hormone receptors (American Cancer Society, 2017). Lastly, targeted
therapy involves the treatment of the cancer’s specific genes, proteins, or tissue
environment. This is a very focused treatment that works differently than chemotherapy to
block the growth and spread of cancer cells while minimizing damage to healthy cells
(American Cancer Society, 2017).
While these procedures and treatments have shown to be effective, each carries its
own set of disadvantages. Surgery is prone to infection or excessive bleeding, along with
long recovery times. There is also the threat of damage to nearby tissues. Radiation therapy
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can result in the hardening of the arteries, soreness, skin irritation, and swelling (American
Cancer Society, 2017). Chemotherapy has side effects such as heart or nerve damage,
damage to normal cells, fatigue, hair loss, and nausea and vomiting (American Cancer
Society, 2017). Hormonal therapy side effects include bone and joint pain, bone thinning,
nausea, headaches, and weight gain. The side effects of targeted therapy include pain,
seizures, changes in mood or thinking, fatigue, and swelling (American Cancer Society,
2017). This extensive, incomplete list of side effects from existing therapies leads to the
necessity for a novel treatment of breast cancer to lessen the recurrence of cancer and to
rebuild functional tissue within the breast.

1.7 Polyphenols
Polyphenols are naturally occurring compounds that are characterized by their
multiple hydroxyl groups attached to an aromatic ring (Vermerris & Nicholson, 2008).
They are a secondary metabolite of plants and have been of increasing interest for their
defense against UV radiation or aggression by pathogens. There have been more than
8,000 polyphenolic compounds identified in various plant species, and all arise from a
common intermediate, phenylalanine, or shikimic, which is a close precursor (Chung et
al., 1998). Classification of polyphenols is determined by the numbers of phenol rings
they contain and on the basis of structural elements that bind these rings together. The
four main classes of polyphenols are phenolic acids, flavonoids, stilbenes, and ligands
(Pandey & Rizvi, 2009).
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1.7.1 Tannins
Tannins are a subset of polyphenols that are water-soluble and can be classified as
hydrolysable or condensed (Petridis, 2006). The hydrolysable groups exhibit a
polyhydric alcohol core with hydroxyl groups that have been either partially or wholly
esterified by gallic acid or hexahydroxydiphenic acid. The condensed group of tannins
are usually products of polymerized lavan-3-ols and flavan-3,4-diols (Chung et al., 1998).
Tannins are present in many plant-based foods, such as wine, green tea, and coffee
(Pandey & Rizvi, 2009). Research indicates tannins are anti-carcinogenic and are a
possible source of treatment for many different types of cancer (Chung et al., 1998). As
tannins are widely available, they are a promising candidate for a novel, therapeutic
anticancer agent (Stich, H. & Rosin, 1984).

1.8 Previous Work
1.8.1 Tannin Effects on ER+ Breast Cancer
It has been previously demonstrated that ER+ breast cancer is susceptible to the
anti-carcinogenic effects of TA in numerous studies (Bawadi, et al., 2005; Booth et al.,
2013; Fujita, et al., 2001; Ngobili et al., 2015). Some tannins, such as ellagic and gallic
acid, do not exhibit estrogenic activity (Zand, et al., 2000), therefore, more recent studies
have focused on other mechanisms of interference.
We (Booth et al., 2013) have shown that TA causes changes to the morphology of
MCF7 ER+ breast cancer cells from spindle shaped to round cells. We also found that TA
induced significant apoptosis in these cells after 24 hours of treatment. This indicates that
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these cells are sensitive to the apoptotic effects of TA. In addition, cell viability was
decreased and apoptotic activity was increased due to TA exposure. It was determined
that this mechanism is through the activation of caspases 3/7 and 9.

1.8.1 Tannin Effects on HER2+ Breast Cancer
It has been shown that tannins are cytotoxic to HER2+ and trastuzumab-resistant
HER2+ breast cancer cells in a dose-dependent manner (Huang, et al., 2011;
Moongkarndi et al., 2004; Signoretti et al., 2002). The mechanism of tannin action has
been widely studied in HER2+ breast cancer cells (Booth et al., 2013; Jordan and Booth,
2016;submitted; Ngobili et al., 2015).
We (Jordan and Booth, 2016; submitted) showed that TA induces apoptosis in
HER2+ breast cancer cells through a mechanism responsible involving activation of
caspases 3/7 and 9. There was a significant reduction in cell proliferation and growth in
the HER2+ breast cancer cells after exposure to TA.

1.9.3 Tannin Effects on Triple Negative Breast Cancer
Triple negative breast cancer cells do not respond to normal hormonal therapies
(Triple Negative Breast Cancer Foundation, 2017). The effects of tannins and other
chemopreventative agents have been of particular interest and have been the subject of
many different studies using triple negative breast cancer cell lines.
We previously published results (Booth et al., 2013) of a study that used collagen
type-1 beads crosslinked with TA. This was done to further understand the effects of
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tannic acid on different types of breast cancer cell lines. Though the effects of TA were
less significant on the triple negative breast cancer cells when compared to other types of
breast cancer cells, a change in morphology was still observed. In addition, the
proliferation of the treated cells was lower than that of the untreated cells. This indicates
that apoptosis was induced in the triple negative cells that were treated. It was postulated
that this was done via caspase activation. Although not as dramatic as other types of
breast cancers, it was shown that there were elevated levels of caspases 3/7 and 9 when
the cells were treated with TA. The effects of TA on these cells were shown to be both
dose- and time-dependent.
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CHAPTER TWO
MATERIALS AND METHODS
2.1 Collagen Bead Preparation
TA crosslinked collagen beads were prepared as previously described (Booth et al.,
2013; Ngobili et al., 2015). Briefly, a 1mg/ml collagen type I solution was prepared using
a stock solution of 3.1 mg/ml (Advanced Biomatrix, Poway, CA) (Vernon, et al., 2005),.
The TA cross-linked beads were prepared using a Nisco Encapsulation Unit VAR V1
electrostatic syringe pump loaded with a 40:60 of 1.4% alginate:1mg/ml collagen solution
in MilliQ water (Sigma Aldrich, St. Louis, MO). The pump was programmed with the
following settings: Volume: 20 mL, Rate: 10 mL/hr, Dia: 15. The solution was pumped
into a 1.5% CaCl2 (mass/volume) solution (Fisher Scientific; Fair Lawn, NJ). One hour
after formation, the beads were filtered out using a mesh strainer and placed in a TA
crosslinking solution comprised of either 0.1%, 1.0%, or 10.0% (wt/vol) TA/MilliQ water.
Twenty-four hours later, the beads were strained once again in a mesh strainer and then
placed in a 50 mM sodium citrate solution (Fisher) for 3 hours, then strained and stored in
phosphate buffered saline (PBS) at 20oC.

2.2 2D Cell Culture
The pre-adipocyte SW872 cell line and the human HER2+ breast cancer BT474 cell
line were obtained from ATCC (Manassas, VA). The SW872 cells were cultured using
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (ATCC), and
the BT474 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (ATCC).
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To enhance each media type, 10.0% fetal bovine serum (FBS) (Corning Life Sciences),
1.0% antibiotic-atimycotic (AA) (Gibco; Great Island, NY), and 0.2% fungizone (Gibco)
were added. The cells were incubated at 37 oC with 5.0% CO2.

2.3 Cell Seeding on Collagen Beads
Confluent 2D cultures of SW872 cells were trypsinized and counted. For each
experiment, 1.0 x 106 cells were added to 50 ml roller tubes with 10 ml medium containing
TA-crosslinked collagen type I beads. The roller tubes were rotated at 3 rpm and incubated
at 37 oC with 5.0% CO2.

2.4 Co-culture of BT474 cells with TA cross-linked beads with SW872 cells
Confluent

2D

cultures of BT474 cells

were

trypsinized and counted and
1.0 x 105 cells were seeded
per well in a Costar 24-well
Transwell® plate (Corning
Life

Sciences;

Figure 2.1: Co-culture of cells and beads

Corning,

NY). The plate was incubated at 37oC with 5.0% CO2 for 24 hours. Each of the three
concentrations of tannic acid crosslinked beads were put in the Transwells in triplicate.
Growth factor-reduced Matrigel® (Corning Life Sciences) was placed in the well on top
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of the beads and incubated at 37 oC with 5.0% CO2 until the Matrigel solidified.
DMEM/F12 was added to each well and the plate incubated at 37 oC with 5.0% CO2.

2.5 Imaging of Cells
After 24 h, images were acquired of the four different groups of BT474 cells (those
treated with 10% TA, 1.0% TA, 0.1% TA, and those that were untreated). Each well was
imaged 3 times using an Axiovert 40 CFL microscope and Axiocam MRc5 (Zeiss;
Overkochen, Germany). This procedure was repeated after 48 and 72.

2.6 Media Collection
Conditioned media was removed from the cultures and stored in the freezer at 20oC until analysis.

2.7 Protein Collection
BT474 cells were cultured and treated as described above. The protein lysates were
collected using M-PER Mammalian Protein Extraction Reagent (Thermo Scientific;
Rockford, IL) and Halt Phosphatase Inhibitor Cocktail (Thermo Scientific) and Halt
Protease Inhibitor Cocktail (Thermo Scientific) were added. Lysates were cleared by
centrifugation at 10,000 rpm for 10 min at 4 oC. Cleared lysates were transferred to new
tubes and stored in the freezer at -20oC until analysis.
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2.8 Western Blotting
Western analysis was also performed as previously described (Booth et al., 2013).
Using a BCA Protein Assay Kit (Thermo Scientific), protein concentration was
determined. Lysates were combined with Laemmli’s SES Sample Buffer (Boston BioProducts, Boston, MA) and heated for 10 min. Proteins were separated using a 4-15%
Criterion TGX gel (Bio-Rad), and then transferred to nitrocellulose. After blocking for one
hour with 5% non-fat milk in PBS, the membranes were probed with anti-BCL-2, anti-PSAPK, and anti--actin overnight at 4∘C with shaking. The membranes were washed
three times with 0.1% Tween-20 in PBS and incubated with secondary HRP-conjugated
antibodies for 2 hrs at room temperature. The membranes were washed twice with 0.1%
Tween-20 in PBS and rinsed in diH2O. Bands were detected using ECL (enhanced
chemiluminescence; Cell Signaling Tech) and images collected using Fluor-Chem M
(ProteinSimple, San Jose, CA).
2.9 Folin-Ciocalteu Assay
The Folin-Ciocalteu (FC) assay was used as described previously to quantify TA
concentrations in collected conditioned media samples (Ngobili et al., 2015).

2.10 Cell Counts
After treatment and removal of media, cells were trypsinized and counted using a
hemocytometer.
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2.11 Statistical Analysis
The Student’s t-test was used to analyze cell counts and TA concentrations. A pvalue of 0.05 was used.
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CHAPTER THREE
RESULTS AND DISCUSSION

3.1 Imaging
Imaging of the cells after various time points showed from a qualatative
standpoint that the TA is capable of diffusing out of the matrix and killing the breast
cancer cells. After 24 hours, there is a visible reduction in cells in the 10% TA group
(Figure 3.1). After 72 hours, there is a clear reduction in cell number between all three
TA treated groups (Figure 3.2). Brown particulates are also present in some of the
samples, which is inherent of cell death. The control group has had some natural cell
death occur, but there has not been as clear of a reduction in number.

Figure 3.1: Images of BT474 breast cancer cells after treatment time points. Total
magnification: 1000X
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3.2 Cell Counts
To obtain a quantitative assessment of the effects of TA on the cells, cell counts
were performed after 72 hours of a treatment. Figure 3.2 shows that there is a correlation
between the numbers of cells vs. the TA concentration. The 10% TA treatment group
exhibited the fewest number of cells, while the control group exhibited the greatest
numbers of cells. The differences in each group when compared to the control group are
statistically significant, with each having a value of p < 0.05 using the Student’s t-test.

Figure 3.2: Average number of BT474 breast cancer cells in wells after 3 days of
treatment. *p<0.05 using Student’s T-test
3.3 Folin- Ciocalteau Assay
The Folin-Ciocalteau assay is a colorimetric assay conducted to quantify the
concentration of TA found in the media below the Transwell® inserts containing the TA
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crosslinked collagen type I beads. While it demonstrated above that the TA was diffusing
out of the Matrigel® and killing the BT474 cancer cells (Figure 3.1), it is important to
further understand the release profile and determine the minimum concentration that is
effective in inducing apoptosis. The results of this assay are shown in Figure 3.3.

Figure 3.3: %TA found in media under wells after 3 days of treatment. No statistical
difference was found between groups.

Figure 3.3 indicates there is an increasing trend observed among the increasing
%TA treatment groups. However, it is important to note that the reagent used in this
assay reacts with the phenol red component of the media. This creates a false positive for
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the presence in the control group that contained no TA. For instance, the chart indicates
that there is almost 4% TA in the group that contained no TA. The presence of phenol red
in the media could be the reason for these seemingly high levels of TA in all of the
groups. It can also be hypothesized that more TA had been metabolized by cells in the
10%TA treated group, which can produce misleading results. If more TA has been
metabolized by the cells, less will be present in the media. This could explain why the
varying concentrations of TA found in the experimental groups do not increase by the
same magnitude as the values they were treated with. While not entirely accurate, this
assay does show that there is an increasing amount of TA that correlates with an increase
in the concentration of TA that the groups were treated with and serves as a good visual
representation of this.

3.4 Western Blotting

Figure 3.4: Western Blot results for Bcl-2, P-SAPK, and -actin. Lane 1: Ladder. Lane 2:
Control. Lane 3: 0.1%TA treated cells. Lane 4: 1.0% TA treated cells. Lane 5:10% TA
Treated cells.
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Figure 3.5: Regulation of Apoptosis Pathway
The results exhibited that not only is TA capable of diffusion out the matrix, but
also that it kills the cancer cells via a different path in the apoptosis pathway than
originally thought. The western blot for the Bcl-2 protein indicates that there is no
difference between the controls and the TA-treated groups (Figure 3.4). It has been
previously shown that TA induces apoptosis through caspase 3/7 and 9. Rather than
affecting the mitochondria, as was originally thought, it would appear that the pathway is
initiated due to endoplasmic reticulum (ER) stress (Figure 3.5). The western blot for PSAPK (denoted JNK in the apoptosis pathway) indicated a difference between the 0.1%
and control vs. the 1.0% and 10.0% groups. Further investigation is necessary to
determine the mechanism of TA-induced apoptosis. Figure 3.4 shows the apoptosis
pathway and the different proteins mentioned have been circled.
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CHAPTER FOUR
CONCLUSIONS
4.1 Conclusions
Seeding TA crosslinked collagen type I beads with human pre-adipocytes forms
the basis for an injectable soft tissue regeneration matrix. This matrix has
chemotherapeutic properties against breast cancer. When the TA crosslinked beads of
varying TA concentrations had been seeded with human pre-adipocytes were placed in a
hydrogel and then used to treat HER2+ breast cancer cells, it was shown that the TA was
capable of diffusing out of the matrix and inducing apoptosis in the breast cancer cells.
As the adipocytes attach and grow on the TA crosslinked beads, they remodel the
collagen and allow for the TA to leach out. The free TA then reacts with breast cancer
cells in the surrounding environment and induces apoptosis.
A Folin-Ciocalteau assay quantified TA in collected conditioned media
demonstrating an increase (Figure 3.3). Qualitative imaging and quantitative cell counts
demonstrated the anti-cancer effects of TA towards the HER2+ breast cancer cells
(Figures 3.1 and 3.2). Western blotting previously demonstrated that TA-induced
apoptosis involved the caspase 3, 7, 9 pathway and we hypothesized that this involved
mitochondrial degradation. Surprisingly, we found that this may not be the case. Western
analysis showed that Bcl-2, a mediator of mitochondrial-controlled apoptosis, is not
involved in TA-induced apoptosis of HER2+ breast cancer cells (Figure 3.4). Instead, we
found that SAPK/JNK is also involved in TA-induced apoptosis of HER2+ breast cancer
cells (Figure 3.4) suggesting endoplasmic reticulum stress as a mediator of TA-induced
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apoptosis. Further analysis will need to be conducted in order to further investigate this,
as the mitochondrial pathway is not ruled out.
The findings of this research conclude that TA crosslinked collagen type I beads
loaded with adipocytes and placed in a matrix are a possible novel tissue regeneration
platform with anti-cancer properties.

4.2 Future Research
While much progress has been made on this project, there is still much more to be
done to improve the procedures and progress it towards clinical application.
One of the main questions that still needs to be answered is the correct size of bead
to use. The beads must be small enough to be delivered through a needle without being
damaged by rupturing or other structural damage, but must also be big enough for cell
loading and survival in vivo. There is batch-to-batch variation between the beads, so it is
necessary to determine a way to consistently create the same size bead.
Additionally, the most effective concentration of TA will need to be determined.
The three concentrations used for my purposes encompassed a broad range and the
concentration will need to be much more specific in future experiments. It is critical that
the lowest concentration that is still effective in killing the cancer cells is determined. This
therapeutic dose will help maximize effectiveness of the TA while minimizing local
toxicity.
There is also a need to find a hydrogel that can be delivered into humans. Matrigel®
is not ideal because it is derived from cancer cells. It serves well as a proof of concept, but
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is not ideal for actual use. The ideal hydrogel will be thermoresponsive so it is a liquid at
room temperature and solidifies at body temperature, will be porous to TA, able to hold
the beads in place, and allow for cell proliferation.
Another important question that needs to be further investigated is the half-life of
TA. This is important because it can help determine how long TA will stay in the body
once it is injected. Once again, it is important to minimize local area toxicity. This will also
aid in determining the highest adipocyte cell seeding density on the beads without taking
away from the chemotherapeutic effects of TA against the breast cancer cells.
It has been previously shown that TA has a chemotherapeutic effect against
different types of breast cancer by inducing apoptosis of the cells via the caspase pathways.
However, there is a need to further understand the mechanism in which TA works against
the breast cancer cell types that have been tested. The pathway does involve the
mitochondria, but could possibly be due to endoplasmic reticulum stress, as was shown in
the western blots.
Further investigation could verify that this therapy is useful as a treatment for other
soft tissue cancer types such as skin cancer. A better understanding of the therapeutic
mechanism in which TA kills cancer cells could lead to the discovery of its uses for many
more clinical areas.
After identifying the optimal components of the injectable matrix, the next step to
be taken is performing in vivo studies to validate the clinical potential of TA and this matrix
as an alternative therapeutic treatment option for patients with breast cancer.
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